{"doi":"10.1002/cpim.116","title":"Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies","abstract":"SARS-CoV-2 is a recently emerged human coronavirus that has escalated to a pandemic. There are currently no approved vaccines for SARS-CoV-2, which causes severe respiratory illness or death. Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Here we describe two methods for evaluating the neutralization capacity of SARS-CoV-2 antibodies. The basic protocol is a focus reduction neutralization test (FRNT), which involves immunostaining infected cells with a chromogen deposit readout. The alternate protocol is a modification of the FRNT that uses an infectious clone-derived SARS-CoV-2 virus expressing a fluorescent reporter. These protocols are adapted for use in a high-throughput setting, and are compatible with large-scale vaccine studies or clinical testing. © 2020 Wiley Periodicals LLC Basic Protocol: Focus reduction neutralization test Alternate Protocol: mNeonGreen-based focus reduction neutralization test (FRNT-mNG).","journal":"Current Protocols in Immunology","year":2020,"id":51159,"datarank":0.7676990718625134,"base_score":5.117993812416755,"endowment":5.117993812416755,"self_citation_contribution":0.7676990718625134,"citation_network_contribution":0.0,"self_endowment_contribution":0.7676990718625134,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":166,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9575,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":218084,"name":"Venkata Viswanadh Edara","orcid":"0000-0001-9321-7839","position":1,"is_corresponding":false},{"id":218085,"name":"Katharine Floyd","orcid":"0000-0002-0866-6961","position":2,"is_corresponding":false},{"id":226152,"name":"Robert C. Kauffman","orcid":"0000-0003-4931-5903","position":3,"is_corresponding":false},{"id":229367,"name":"Grace Mantus","orcid":null,"position":4,"is_corresponding":false},{"id":94484,"name":"Evan J. Anderson","orcid":"0000-0002-1576-4420","position":5,"is_corresponding":false},{"id":104987,"name":"Nadine Rouphael","orcid":"0000-0002-2512-7919","position":6,"is_corresponding":false},{"id":256945,"name":"Sri Edupuganti","orcid":null,"position":7,"is_corresponding":false},{"id":38215,"name":"Pei‐Yong Shi","orcid":"0000-0001-5553-1616","position":8,"is_corresponding":false},{"id":105316,"name":"Vineet D. Menachery","orcid":"0000-0001-8803-7606","position":9,"is_corresponding":false},{"id":226174,"name":"Jens Wrammert","orcid":"0000-0002-1733-4424","position":10,"is_corresponding":false},{"id":106937,"name":"Mehul S. Suthar","orcid":"0000-0002-2686-8380","position":11,"is_corresponding":false},{"id":106936,"name":"Abigail Vanderheiden","orcid":"0000-0003-1321-4510","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T20:40:28.278215Z","pmid":"33215858","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}